827031-83-4
827031-83-4
Chemical Structure
Verubulin
Synonym(s): MPC 6827
- CAS No.: 827031-83-4
- Formula:C17H17N3O
- Molecular Weight:279.34
IUPAC Name: N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine
InChIKey: SNHCRNMVYDHVDT-UHFFFAOYSA-N
SMILES: CC1=NC(N(C2=CC=C(OC)C=C2)C)=C3C=CC=CC3=N1
Biological Activity: Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Verubulin | 99.85% | Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.98
HY-12098Verubulin hydrochloride -
Similarity Score 0.88
HY-129715MPI-0441138 -
Similarity Score 0.71
HY-144748Tubulin inhibitor 17 -
Similarity Score 0.68
HY-149363Tubulin polymerization-IN-43 -
Similarity Score 0.68
HY-161824Antiproliferative agent-52 -
Similarity Score 0.66
HY-103566ALY456236 free base -
Similarity Score 0.66
HY-103566RLY456236 (Standard) -
Similarity Score 0.66
HY-18947SKLB-23bb -
Similarity Score 0.66
HY-180347HD-800 -
Explore the MedChemAI to find more analogs
References
- [1]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]
- [2]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]
- [3]. Jones J T, et al. Comparison of MPC-6827 activity in xenograft models with different dosing schedules. Journal of Clinical Oncology, 2011, 29(15_suppl): e13080-e13080.
